Hematology

Latest News

Venetoclax showed “remarkable efficacy” in older patients, with an response rate of 91% in the octogenarian group—similar to what has been reported in younger cohorts. | Image credit: sovova - stock.adobe.com
Venetoclax Effective in Older Patients With CLL

June 20th 2025

Venetoclax demonstrated impressive efficacy in octogenarians with CLL, although treatment management posed some challenges.

Venetoclax duration did not have a significant impact on overall survival based on univariate analysis in patients with AML or MDS. | Image credit: Sviatlana-stock.adobe.com
Venetoclax Duration Does Not Significantly Impact OS in AML or MDS

June 18th 2025

Acute myeloid leukemia cells | Image credit: LASZLO - stock.adobe.com
Revumenib Shows Efficacy in Patients With AML and Genetic Alterations

June 12th 2025

The tablet formulation of zanubrutinib (Brukinsa; BeOne) is now approved for all 5 indications across several hematological cancers.  | Image credit: wladimir1804 - AdobeStock_408414612
FDA Approves Tablet Formulation of Zanubrutinib for All Indications

June 11th 2025

Mansi Shah, MD
Stem Cell Transplant Remains Cost-Effective Option for MM: Mansi Shah, MD

June 11th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo